๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Trials with a site in Zhengzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
NCT07738679Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
NCT06208410Advanced Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2
306
Zhengzhou
2024-01-11
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
NCT05944224Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xiโ€™an
2023-10-17
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

9 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 13 studies
PhaseStudiesRecruitingShare
Phase 1/27553.8%
Phase 15438.5%
Phase 2107.7%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Ascentawits Pharmaceuticals, Ltd10
BeOne Medicines11
Changchun GeneScience Pharmaceutical Co., Ltd.11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.10
Foresight Therapeutics (Hefei) Co., Ltd.10
Genfleet Therapeutics (Shanghai) Inc.11
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.11
Jiangsu HengRui Medicine Co., Ltd.11
MediLink Therapeutics (Suzhou) Co., Ltd.11
Risen (Suzhou) Pharma Tech Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.